Galapagos Coasts Through Recession On Deals With Merck And Other Big Pharmas
This article was originally published in The Pink Sheet Daily
Executive Summary
Low-commitment, option-based alliances with Big Pharma bolster Belgian biotech’s own pipeline.
You may also be interested in...
Deals Of The Week: Merck/Galapagos, Merck/Medarex, GSK/Stiefel ...
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
Deals Of The Week: Merck/Galapagos, Merck/Medarex, GSK/Stiefel ...
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
GSK Tries to Mimic Real-World Biotech
Not satisfied with its R&D experiments to date, GSK has taken its most radical step yet toward re-creating biotech within its walls: even smaller units complete with investment boards occupied by external VCs and CEOs and milestone-based funding and external VCs.